D
Desi Peneva
Researcher at Precision Health Economics
Publications - 27
Citations - 865
Desi Peneva is an academic researcher from Precision Health Economics. The author has contributed to research in topics: Health care & Population. The author has an hindex of 9, co-authored 24 publications receiving 603 citations. Previous affiliations of Desi Peneva include Illinois State University.
Papers
More filters
Journal ArticleDOI
Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical Research
Dana P. Goldman,David M. Cutler,John W. Rowe,Pierre-Carl Michaud,Jeffrey Sullivan,Desi Peneva,S. Jay Olshansky +6 more
TL;DR: Overall, greater investment in research to delay aging appears to be a highly efficient way to forestall disease, extend healthy life, and improve public health.
Journal ArticleDOI
Short-term costs of preeclampsia to the United States health care system.
Warren Stevens,Tiffany Shih,Devin Incerti,Thanh G.N. Ton,Henry C. Lee,Desi Peneva,George A. Macones,Bahaeddine M Sibai,Anupam B. Jena +8 more
TL;DR: In 2012, the cost of preeclampsia within the first 12 months of delivery was $2.18 billion in the United States ($1.03 billion for mothers and $1.15 billion for infants), and was disproportionately borne by births of low gestational age.
Journal ArticleDOI
The Rising Burden of Preeclampsia in the United States Impacts Both Maternal and Child Health.
Tiffany Shih,Desi Peneva,Xiao Xu,Amelia Sutton,Elizabeth W. Triche,Richard A. Ehrenkranz,Michael J. Paidas,Warren Stevens +7 more
TL;DR: Preeclampsia is one of the top six causes of maternal mortality in the United States and is associated with considerable perinatal morbidity and mortality, but these conditions currently lack effective treatment.
Journal ArticleDOI
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.
Warren Stevens,Desi Peneva,Jim Z. Li,Larry Z. Liu,Gordon G. Liu,Runlin Gao,Darius N. Lakdawalla +6 more
TL;DR: In light of its aging population and epidemiological transition, China faces near-certain increases in CVD morbidity and mortality, and preventative measures such as effective lipid and blood pressure management may reduce CVD burden substantially and provide large social value.
Journal ArticleDOI
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
Darius N. Lakdawalla,Jason Shafrin,Ningqi Hou,Desi Peneva,Seanna Vine,Jinhee Park,Jie Zhang,Ron Brookmeyer,Robert A. Figlin +8 more
TL;DR: Real-world OS treatment benefits were similar to those observed in RCTs based on OS endpoints, but were 16% less than RCT efficacy estimates based on surrogate endpoints; these results, however, varied by tumor and line of therapy.